ABT vs SPXC · P/E 25, rev $44.33B vs P/E 46, rev $1.98B
Abbott Laboratories (ABT) versus SPX Corp (SPXC) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
SPX Corp (SPXC) is a building products & equipment company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported SPXC revenue for 2024-12-31 was $1.98B. Net income was $200.5M. Revenue was up 13.9% from 2023-12-31 to 2024-12-31. SPXC currently screens at market cap $12.06B and trailing P/E 46.0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. SPXC currently screens at market cap $12.06B and trailing P/E 46.0.
Not investment advice. Open the ABT and SPXC stock pages for the full models.
Not investment advice.